Effectiveness and Safety of Percutaneous Thrombectomy Devices: Comparison of Rotarex and Angiojet in a Physiological Circulation Model.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 28 04 2019
revised: 13 12 2019
accepted: 13 01 2020
pubmed: 18 2 2020
medline: 25 6 2020
entrez: 18 2 2020
Statut: ppublish

Résumé

To compare the percutaneous Rotarex and Angiojet thrombectomy devices with regard to effectiveness and in vitro safety. The Rotarex and Angiojet devices were evaluated in an established in vitro pulsatile flow model with a human femoropopliteal vessel phantom. First pass recanalisation and thrombus weight were assessed after thrombectomy, as well as micro- and macro-emboli. Further, histological evaluation of the vascular phantom was performed to analyse vascular injuries. Thrombus weight did not differ significantly prior to the thrombectomy between the groups, but the Rotarex showed slight advantages in thrombus removal vs. the Angiojet regarding first pass recanalisation. Micro- and macro-emboli occurred in most of the endovascular manoeuvres performed; however, significantly more macro-emboli (2.37 ± 1.51 vs. 0.87 ± 0.83; p = .048) were observed using the Rotarex than the Angiojet. Macroscopic dissections were detected in the Rotarex group (n = 3) but not in the Angiojet group. Microscopic vascular injuries were detected significantly more often in the Rotarex group (Rotarex: 531.61 μm ± 102.81 μm; Angiojet: 705.42 μm ± 61.68 μm [p = .001]). Both devices showed a comparable performance, with a slight advantage for the Rotarex regarding first pass recanalisation. Significantly more thrombo-emboli, and vascular injuries were observed in the Rotarex group with the latter being obviously the more tissue preserving procedure but potentially with a lower rate of recanalisation. Based on the present results, clinical randomised trials, including long term follow up, are needed to optimise and improve the use of catheter based procedures, taking into account the thrombus entity, localisation, and clinical history.

Identifiants

pubmed: 32063465
pii: S1078-5884(20)30062-9
doi: 10.1016/j.ejvs.2020.01.016
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

983-989

Informations de copyright

Copyright © 2020 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Auteurs

René Rusch (R)

Department of Cardiovascular Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany. Electronic address: rene.rusch@uksh.de.

Jens Trentmann (J)

Department of Radiology and Neuroradiology, University Hospital of Schleswig-Holstein, Kiel, Germany.

Lars Hummitzsch (L)

Department of Anaesthetics and Intensive Care Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.

Melanie Rusch (M)

Department of Orthopaedics and Trauma Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany.

Schekeb Aludin (S)

Department of Radiology and Neuroradiology, University Hospital of Schleswig-Holstein, Kiel, Germany.

Assad Haneya (A)

Department of Cardiovascular Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany.

Martin Albrecht (M)

Department of Anaesthetics and Intensive Care Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.

Thomas Puehler (T)

Department of Cardiovascular Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany.

Jochen Cremer (J)

Department of Cardiovascular Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany.

Rouven Berndt (R)

Department of Cardiovascular Surgery, University Hospital of Schleswig-Holstein, Kiel, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH